Latest Conference Articles

An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

Approximately 88% of patients treated with SER-109 achieved a sustained clinical response at 8 weeks.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

PROSE allows patients to report their symptoms of dysphagia in real-time.

Investigators found fistulizing Crohn’s disease increases the healthcare burden and lengthens the duration of hospital stays in patients with acute kidney injuries.

Biologic therapies show promising results of clinical remission in patients with Crohn's disease.

It can be challenging to find a suitable donor for fecal microbiota transplantation.

Dr. Aljaras talks about the importance of focusing on diet when examining irritable bowel syndrome.

Patients with Crohn's disease often also suffer from kidney dysfunction.

This patient group had higher odds of death and longer lengths of hospital stays.

Patients in both the ADVANCE and MOTIVATE studies achieved enhanced clinical response and endoscopic response.

Hypertension rates were low in both ulcerative colitis and multiple sclerosis patients treated with ozanimod, regardless of concurrent SNRI/SSRI use.

Investigators propose oral treprostinil be considered when treating patients with pulmonary arterial hypertension.

The retina field is equipped with ideal therapy and research informing implementation. Now it needs greater patient buy-in.

Assessment from a patient survey showed an association between increased rates of injection treatment and increased restriction on usual activity for patients.

Rishi P. Singh, MD, discusses new VISTA/VIVID data showing what really influences a patients' likelihood and time to DME resolution when treated with aflibercept.

Theodore Leng, MD, MS, defines the trends of patient discontinuation, and how direct caregivers may help to reduce risk of losing patients.

Arshad Khanani, MD, MA, explains how new measures made available to ophthalmology will help address a quickly growing patient population.

There were no episode of gastrointestinal bleeding, transfusion of packed red blood cells, or octreotide infusions observed.

Investigators collected data from several studies which tested the efficacy of the ointment on pediatric populations affected by atopic dermatitis and their families.

Veeral S. Sheth, MD, MBA, discusses what ophthalmologists will need to learn about PDS application for patients with AMD.

Theodore Leng, MD, MS, discusses new findings based on IRIS registry data showing long-term discontinuation trends in patients.

An approval may be pending for the unique delivery system. An expert explains its benefit for nAMD patients and physicians alike.

Dr. Ponder continued his discussion on technology use in pediatric T1D care, focusing on a multidisciplinary care angle and different concepts in treatment.

Investigators reported that machine learning was non-invasive and accessible to a large array of clinicians, and could help prevent infants from developing atopic dermatitis.

Dr. Carbone presented about autism management during the 2021 AAP virtual conference.

Dr. Ponder discusses the importance of both clinician and patient learning about new diabetic technologies, focusing on their utility and limitations in the care process.